With all eyes on the race to get the autologous cell immunotherapies to market, Kite announces it could soon see late-stage data on its lead candidate.
Kite Pharma Inc. a major player in autologous chimeric antigen receptor T-cell (CAR-T) therapies aimed at B-cell malignancies, is expecting late-stage data for its lead candidate, KTE-C19, in diffuse large B-cell lymphoma very soon.
The company indicated during its second-quarter earnings call that it will be getting top-line data from the ZUMA-1 study of...
With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.
The Austrian firm is delisting from the NASDAQ and closing down.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
